Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

LiquidThetaOptions Nov. 25 at 9:31 PM

💎 LiquidTheta® Live Actionable Trade Asset: $JNJ Contracts: $JNJ December 18, 2026 $210 Calls Scale in: $13.47- $16.46 Scale out: $52.37-$89.77 Profit Potential : 281% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

BEATOFtheMARKET Nov. 25 at 7:51 PM

$JKHY $JNJ $JOBX $JPM $JPST

0 · Reply

Austero Nov. 25 at 6:18 PM

$CUBT 2026 🎯 $BHC $JNJ $RHHBY $TAK

1 · Reply

dogDazeSummer Nov. 25 at 2:03 PM

Another Alzheimer’s graveyard perhaps the key will be someday unlock by —- combining 2-3 of these drugs with something that also reduces neuro-inflammation. $AMGN $BIIB and $IFRX get it. But tough pill for $JNJ P2 data: https://www.fiercebiotech.com/biotech/jjs-5b-alzheimers-hope-fades-anti-tau-antibody-posdinemab-flops-phase-2

1 · Reply

ZacksResearch Nov. 25 at 12:38 PM

$JNJ has ripped nearly 17% in just three months — but is the move done or just getting started? JNJ’s 16.7% rise is riding on stronger sales guidance, rapid pipeline advances and improving MedTech momentum as the sector recovers. That’s a powerful trio of catalysts. Full buy/sell/hold breakdown here 👉 https://www.zacks.com/stock/news/2795171/jj-up-around-17-in-3-months-should-you-buy-sell-or-hold-the-stock?cid=sm-stocktwits-2-2795171-teaser-22317&ADID=SYND_STOCKTWITS_TWEET_2_2795171_TEASER_22317

0 · Reply

ZacksResearch Nov. 25 at 11:38 AM

$JNJ has had a strong start to the year — but is it time to hold? 🚀 With a 42.5% YTD surge, J&J has been outpacing its sector and the S&P 500, despite facing headwinds like the Stelara patent cliff and legal battles. The Zacks Consensus Estimate for 2026 earnings is also on the rise, signaling confidence in sustained growth. J&J is currently a Zacks Rank #3 (Hold) stock. Full analysis here 👉 https://www.zacks.com/stock/news/2795171/jj-up-around-17-in-3-months-should-you-buy-sell-or-hold-the-stock?cid=sm-stocktwits-2-2795171-body-22316&ADID=SYND_STOCKTWITS_TWEET_2_2795171_BODY_22316

0 · Reply

Iightning Nov. 25 at 10:09 AM

1ightning® Options Trade Alert (Actionable) | Buy $JNJ Dec 5 $208 Call | Enter: $1.18 Exit: $1.86 | Profit: 57.89% ROI | https://1ightning.com

0 · Reply

HedgeAlerts Nov. 25 at 2:32 AM

Hedge Alert Live - Protect Your Portfolio Contract: $JNJ $205.00 Put · DEC 05, 2025 Exp Entry Price: $3.05 - $3.10 Exit Price Target: $6.86 Profit Margin: +125% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

Jessdog77 Nov. 25 at 1:42 AM

$JNJ all EOD 🤔

0 · Reply

Jessdog77 Nov. 25 at 1:41 AM

$JNJ what’s the news here? Or awaiting news?

0 · Reply

JNJ Stock vs. PFE Stock: Which Pharmaceutical Giant Is A Better Buy?

PFE

Nov 18, 2025, 4:21 PM EST - 7 days ago

Why biotech and drug stocks are on the mend even though the rest of the market is hurting

AZN LLY MDT MRK NVO OLMA PFE

Nov 18, 2025, 8:25 AM EST - 7 days ago

Global drugmakers rush to boost US presence as tariff threat looms

ABBV AMGN AZN BIIB GILD GSK LLY

Nov 17, 2025, 6:07 PM EST - 7 days ago

Vida Ventures Marks Fourth Major Portfolio Acquisition in 2025, Capping a Record-Setting Year for Its Science-Led, Discipline-Driven Strategy

Nov 17, 2025, 1:17 PM EST - 8 days ago

Johnson & Johnson (JNJ) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript

Nov 17, 2025, 8:29 AM EST - 8 days ago

Johnson & Johnson to Buy Halda Therapeutics For $3.05 Billion

Nov 17, 2025, 8:15 AM EST - 8 days ago

Halda Therapeutics Announces Acquisition by Johnson & Johnson

Nov 17, 2025, 8:07 AM EST - 8 days ago

J&J to buy cancer therapy developer Halda Therapeutics for $3.05 billion

Nov 17, 2025, 8:05 AM EST - 8 days ago

New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis

Nov 17, 2025, 8:00 AM EST - 8 days ago

Johnson & Johnson Set to Revolutionize the Treatment of Cancer With the Acquisition of Halda Therapeutics

Nov 14, 2025, 3:19 PM EST - 11 days ago

Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman

ABBV AZN LLY MRK NVO PFE XLV

Nov 14, 2025, 8:03 AM EST - 11 days ago

Bristol Myers, J&J halt heart drug trial after interim review

BMY

Nov 11, 2025, 1:41 PM EST - 14 days ago

Johnson & Johnson (JNJ) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 11, 2025, 12:51 PM EST - 14 days ago

Johnson & Johnson (JNJ) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript

Nov 10, 2025, 6:26 AM EST - 15 days ago

Johnson & Johnson: 2 Recent FDA Wins And Earnings Beat Warrant 'Buy' Rating

Nov 7, 2025, 12:57 PM EST - 18 days ago

FDA Clears Johnson & Johnson's Darzalex Faspro, Enabling Early Intervention In Myeloma Progression

Nov 7, 2025, 5:40 AM EST - 18 days ago

Johnson & Johnson: Dividends Don't Lie

Nov 6, 2025, 5:07 PM EST - 19 days ago

DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma

Nov 6, 2025, 9:54 AM EST - 19 days ago

Cramer's Mad Dash: Johnson & Johnson

Nov 6, 2025, 7:34 AM EST - 19 days ago

US FDA expands use of J&J's Caplyta as add-on depression drug

Nov 6, 2025, 7:30 AM EST - 19 days ago

FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder

Nov 5, 2025, 4:50 PM EST - 20 days ago

Johnson & Johnson to Participate in the Citi's 2025 Global Healthcare Conference

Nov 1, 2025, 10:25 AM EDT - 24 days ago

Best Dividend Aristocrats For November 2025

ABBV ABT ADM ADP AMCR AOS ATO

Oct 29, 2025, 8:05 AM EDT - 27 days ago

Johnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting

Oct 29, 2025, 5:11 AM EDT - 27 days ago

Best Dividend Kings: October 2025

ABBV ABM ABT ADM ADP AWR BDX

Oct 28, 2025, 6:15 PM EDT - 4 weeks ago

Levin Papantonio Announces Jury Awards $20 Million Verdict in Talc Mesothelioma Case Casaretto Estate v. Johnson & Johnson

Oct 28, 2025, 9:25 AM EDT - 4 weeks ago

J&J Stock Can Fall

Oct 28, 2025, 9:13 AM EDT - 4 weeks ago

Texas sues J&J and Kenvue, claiming they hid Tylenol's autism risks

KVUE

Oct 27, 2025, 8:00 AM EDT - 4 weeks ago

New study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile

Oct 27, 2025, 7:30 AM EDT - 4 weeks ago

TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years

Oct 27, 2025, 7:30 AM EDT - 4 weeks ago

Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis

Oct 24, 2025, 6:32 PM EDT - 4 weeks ago

Published in The Lancet: Nipocalimab significantly decreased Sjögren's disease (SjD) activity and severity through substantial reduction in Sjögren's-related autoantibodies

Oct 24, 2025, 8:00 AM EDT - 4 weeks ago

Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis

Oct 24, 2025, 4:30 AM EDT - 4 weeks ago

Smart Acquisitions And Profit Margin Growth Amid Strategic Repositioning

APD CNC COF FISV IQV IVZ LRCX

Oct 23, 2025, 10:52 AM EDT - 4 weeks ago

These low-risk stocks could be a profitable answer to this volatile earnings season

AMGN BMY CVS GD GIS HQY HRL

Oct 22, 2025, 4:36 PM EDT - 4 weeks ago

Johnson & Johnson to Participate in the 7th Annual Wolfe Research Healthcare Conference

Oct 22, 2025, 2:00 PM EDT - 4 weeks ago

Johnson & Johnson Stock To $134?

Oct 19, 2025, 10:30 AM EDT - 5 weeks ago

Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer

Oct 16, 2025, 8:00 AM EDT - 5 weeks ago

TECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of care

Oct 15, 2025, 7:03 PM EDT - 5 weeks ago

J&J faces first UK lawsuits alleging its baby powder caused cancer

Oct 15, 2025, 2:04 PM EDT - 5 weeks ago

These Analysts Boost Their Forecasts On Johnson & Johnson After Upbeat Q3 Earnings

Oct 15, 2025, 1:56 PM EDT - 5 weeks ago

Johnson & Johnson Rules Out Big Acquisitions, Reiterates Focus On Small Deals: Analyst

Oct 15, 2025, 7:51 AM EDT - 5 weeks ago

Johnson & Johnson reveals 2025 sales forecast and plans for its orthopedics business

Oct 14, 2025, 7:30 PM EDT - 5 weeks ago

'NEVER BEEN STRONGER': Johnson & Johnson leader touts latest innovations

Oct 14, 2025, 12:36 PM EDT - 6 weeks ago

Johnson & Johnson (JNJ) Q3 2025 Earnings Call Transcript

Oct 14, 2025, 10:01 AM EDT - 6 weeks ago

Citi (C) Posts Strong Earnings, Stuffed Crust Strengthens DPZ, JNJ Slides

C DPZ

Oct 14, 2025, 8:58 AM EDT - 6 weeks ago

Johnson & Johnson Q3 Earnings Surprise, Icotrokinra Shines Again

Oct 14, 2025, 8:56 AM EDT - 6 weeks ago

Johnson & Johnson to spin off orthopedics unit after raising 2025 sales forecast

Oct 14, 2025, 8:51 AM EDT - 6 weeks ago

Johnson & Johnson To Separate Orthopedics Business, Boosts Annual Sales Outlook

Oct 14, 2025, 7:44 AM EDT - 6 weeks ago

Johnson & Johnson's stock heads for a record after a profit beat and plans for another spinoff

LiquidThetaOptions Nov. 25 at 9:31 PM

0 · Reply

BEATOFtheMARKET Nov. 25 at 7:51 PM

$JKHY $JNJ $JOBX $JPM $JPST

0 · Reply

Austero Nov. 25 at 6:18 PM

$CUBT 2026 🎯 $BHC $JNJ $RHHBY $TAK

1 · Reply

dogDazeSummer Nov. 25 at 2:03 PM

1 · Reply

ZacksResearch Nov. 25 at 12:38 PM

0 · Reply

ZacksResearch Nov. 25 at 11:38 AM

0 · Reply

Iightning Nov. 25 at 10:09 AM

1ightning® Options Trade Alert (Actionable) | Buy $JNJ Dec 5 $208 Call | Enter: $1.18 Exit: $1.86 | Profit: 57.89% ROI | https://1ightning.com

0 · Reply

HedgeAlerts Nov. 25 at 2:32 AM

0 · Reply

Jessdog77 Nov. 25 at 1:42 AM

$JNJ all EOD 🤔

0 · Reply

Jessdog77 Nov. 25 at 1:41 AM

$JNJ what’s the news here? Or awaiting news?

0 · Reply

Jimmyshillcramer Nov. 25 at 1:39 AM

$ANVS well the rest of them sucks so maybe this treatment gets lucky sooner or later one might work … $NVO $JNJ $AVXL $SAVA who knows take a shot get rich or poor

1 · Reply

Night_Owl_Biotech Nov. 25 at 1:10 AM

$LEGN 's market cap is a disgrace when compared to analyst revenue estimates. Today LEGN hit its 52-week low while the XBI is trading at multi-year highs. LEGN management & BOD need to consider a sale to maximize shareholder value because, clearly, their plan is not working. The attachment compares the valuations paid to acquire 5 LEGN peers as multiples of projected revenues. Peers are those comm'l-stage bios projected to generate, more or less, the same revenue dollars over the next 4-10 years. Note LEGN trades for 0.17X their cumulative 10-year analyst revenue estimates. The 5 were acquired for 0.32X to 0.49X. LEGN's true gross margin profile is not clear to us but the peers' gross margins are not "off-the-charts" competitive. The odds of LEGN scoring a 2nd approval are dismal (consistent with any bio). Why in the world $JNJ does not simply buy them. Everyone wins in M&A, especially healthcare costs in general via consolidation. $XBI $IBB

2 · Reply

QuantInsider Nov. 25 at 12:48 AM

What's the move on $JNJ? Seeing strong bullish vibes here Repeated 1,440-lot ask-side blocks in Dec 19 $185 calls, eclipsing prior OI of 5,072 on InsiderFinance, show concentrated long delta build That's a big signal for continuation Up 3.02% over the last 5 days and 1.05% today Flow's all calls and ITM heavy, so favoring continuation setups Even the posdinemab Alzheimer's study discontinuation didn't shake things up Price and flow are in sync, not news driven Looking solid for defined risk longs

0 · Reply

Iightning Nov. 24 at 11:02 PM

1ightning® Options Trade Alert (Actionable) | Buy $JNJ Dec 5 $208 Call | Enter: $1.18 Exit: $1.86 | Profit: 57.89% ROI | https://1ightning.com

0 · Reply

Quantumup Nov. 24 at 7:44 PM

Guggenheim reiterated $ACLX Buy-$120 and said—'Stock Weakness Seems Overdone' $LEGN - $JNJ $GILD Guggenheim— Arcellx inc. shares are under pressure this afternoon following disclosure of a late-breaking ASH abstract from a potential competitor, Kelonia Therapeutics, highlighting the first anecdotal Ph 1 clinical data on 3 relapsed or refractory multiple myeloma (RRMM) patients that received lentiviral in vivo CAR-T gene therapy KLN-1010 — while the abstract highlights "promise and potential feasibility of this approach," the stock reaction seems overdone, given the early nature of the data with limited follow-up and the absence of long-term safety data.

0 · Reply

Lectin_Pectin Nov. 24 at 7:09 PM

$BIIB $MRK will want to buy. Worth several billion. Maybe even $JNJ https://www.reddit.com/r/pennystocks/comments/1p5hf7g/gain_therapeuticsganx_has_returned_smell_to/?share_id=NeFe1EG_VIH3MRaJM6jgD&utm_content=1&utm_medium=android_app&utm_name=androidcss&utm_source=share&utm_term=9

1 · Reply

Lowlow1 Nov. 24 at 4:11 PM

$JNJ >Shph stock its time its at its bottom getting ready to bounce u find a good spot to get in at an sondq🤑!

0 · Reply

NetworkNewsWire Nov. 24 at 2:46 PM

Biotech Valuations Rise as New Clinical Platforms Show Progress $OTLC $IOVA $MRK $LLY $JNJ https://ibn.fm/q1O2N

0 · Reply

MoneyGroupLLC Nov. 24 at 9:38 AM

Enter: $JNJ Calls Strike Price: $210 Expiry Date: DEC 19 2025 Buy in Price: $1.81 - $1.93 Sell Price: $3.96 Profit : +119% (Turn every $1 into $2.19) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

LiquidThetaOptions Nov. 24 at 3:52 AM

💎 LiquidTheta® Live Actionable Trade Asset: $JNJ Contracts: $JNJ December 18, 2026 $210 Calls Scale in: $14.01- $17.12 Scale out: $54.49-$93.41 Profit Potential : 218% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

stockanalysis_ Nov. 24 at 3:37 AM

Biggest Pharmaceutical Stocks: $LLY $JNJ $ABBV $AZN $NVS Bookmark this page: https://stockanalysis.com/list/pharmaceutical-stocks/?ref=saveontrading

0 · Reply

BioRich Nov. 24 at 2:45 AM

$TERN getting some (more) attention now. Possible tie to $SNY or $JNJ (thanks $ALT board and ChatGPT). I'll take that! Follow/subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some money. Cheers!

2 · Reply

Market Cap	491.26B
Revenue (ttm)	88.82B
Net Income (ttm)	14.07B
EPS (ttm)	N/A
PE Ratio	19.56
Forward PE	18.69
Profit Margin	15.84%
Debt to Equity Ratio	0.50

Volume	10,273,675
Avg Vol	9,093,334
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	94%
Beta	0.38
Analysts	Strong Sell
Price Target	$203.50